Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.47 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
| ▸ | PPIA | P62937 | 3/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2077409 | 0.79 | HSP90AB1 (0.41) | HSP90AB1PPIA | |
| SCHEMBL2605099 | 0.69 | HSP90AB1 (0.66) | HSP90AB1CSNK1A1TYRO3DYRK1B | |
| SCHEMBL13437200 | 0.69 | HSP90AB1 (0.74) | HSP90AB1 | |
| SCHEMBL4077067 | 0.68 | CSNK1A1 (0.58) | HSP90AB1CSNK1A1TYRO3DYRK1BHCRTR1 | |
| SCHEMBL3797695 | 0.68 | CSNK1A1 (0.58) | HSP90AB1CSNK1A1TYRO3DYRK1BHCRTR1 | |
| SCHEMBL2605018 | 0.67 | HSP90AB1 (0.70) | HSP90AB1CSNK1A1TYRO3DYRK1BPPIA | |
| SCHEMBL2076070 | 0.66 | CSNK1A1 (0.50) | HSP90AB1CSNK1A1TYRO3DYRK1BHCRTR1 | |
| SCHEMBL2076069 | 0.66 | CSNK1A1 (0.50) | HSP90AB1CSNK1A1TYRO3DYRK1BHCRTR1 | |
| SCHEMBL12430906 | 0.65 | HSP90AB1 (0.78) | HSP90AB1 | |
| SCHEMBL2605080 | 0.65 | HSP90AB1 (0.59) | HSP90AB1CSNK1A1TYRO3DYRK1BCDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163750-B2 | Fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone HSP 90 | SANOFI-AVENTIS (FR) | 2012-04-24 | — | — | US | claimed |
| US-8163750-B2 | Fluorene derivatives, compositions containing the same and use thereof as inhibitors of the protein chaperone HSP 90 | SANOFI-AVENTIS (FR) | 2012-04-24 | — | — | US | disclosed |
| US-20100130503-A1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | SANOFI-AVENTIS (FR) | 2010-05-27 | — | — | US | disclosed |
| US-20100130503-A1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | SANOFI-AVENTIS (FR) | 2010-05-27 | — | — | US | disclosed |
| WO-2008049994-A1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | SANOFI-AVENTIS (FR) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130503-A1 | NEW FLUORENE DERIVATIVES, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF AS INHIBITORS OF THE PROTEIN CHAPERONE HSP 90 | HSP90AB2P, HSPA2, HSP90AB1 | HSP90AB1 3/4885CSNK1A1 1212/4885TYRO3 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.